Protara Therapeutics/$TARA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Protara Therapeutics
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
- Ticker
- $TARA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 46
- Headquarters
- New York, United States
- Website
- www.protaratx.com
TARA Metrics
BasicAdvanced
$136M
-
-$1.38
-
-
Price and volume
Market cap
$136M
52-week high
$7.82
52-week low
$2.09
Average daily volume
1.4M
Financial strength
Current ratio
9.01
Quick ratio
8.828
Long term debt to equity
0.008
Total debt to equity
0.017
Profitability
EBITDA (TTM)
-84.86
Management effectiveness
Return on assets (TTM)
-35.36%
Return on equity (TTM)
-57.40%
Valuation
Price to book
0.98
Price to tangible book (TTM)
0.98
Price to free cash flow (TTM)
-1.787
Free cash flow yield (TTM)
-55.95%
Free cash flow per share (TTM)
-1.287
Growth
Earnings per share change (TTM)
-0.54%
3-year earnings per share growth (CAGR)
-39.14%
What the Analysts think about TARA
Analyst ratings (Buy, Hold, Sell) for Protara Therapeutics stock.
Analyst projections of the future price of Protara Therapeutics stock.
TARA Financial Performance
Revenues and expenses
TARA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing TARA
Fund name | Fund size | $TARA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.